Introduction
============

Acetylcholine, produced by enteric neurons (e.g., Harrington et al. [@b21]) as well as by the colonic epithelium (Klapproth et al. [@b29]; Bader et al. [@b4]) is a central regulator of many gastrointestinal functions. The actions of this transmitter are mediated either by muscarinic or nicotinic receptors. Muscarinic receptors are metabotropic, G-protein-coupled receptors with five subtypes (M~1~--M~5~). The muscarinic receptors M~2~ and M~4~ couple to the G~i*α*~ subunit and thus inhibit the adenylate cyclase, whereas M~1~, M~3~, and M~5~ couple to G~q/11*α*~ subunits. The subsequent activation of phospholipase C leads to stimulation of protein kinase C and increased levels of the cytosolic Ca^2+^ concentration (Hirota and McKay [@b23]). Muscarinic receptors are widely expressed in the alimentary tract. The M~1~ subtype has been shown to localize on enteric neurons (Khan et al. [@b28]), on intestinal glands (Wessler and Kirkpatrick [@b50]) as well as on colonic epithelial cells (Haberberger et al. [@b19]; Wessler and Kirkpatrick [@b50]; Khan et al. [@b28]), whereas the M~3~ subtype is localized on the epithelium (Hirota and McKay [@b23]; Wessler and Kirkpatrick [@b50]).

In contrast, nicotinic receptors are homo- or heteropentamers enclosing an ion channel, that is, they function as ionotropic receptors. Until now, the following subunits have been identified in vertebrates: 10 *α* subunits (*α*1--*α*10), four *β* subunits (*β*1--*β*4), one *γ* subunit, one *δ* subunit, and one *ε* subunit. They were classified into neuronal-type and muscle-type nicotinic receptors (Schuller [@b41]). The neuronal nicotinic receptors are either homomers consisting of five identical *α*7, (*α*8), or *α*9 subunits or they are heteropentamers consisting of combinations of *α*2--*α*6 or *α*10 subunits with *β*2--*β*4 subunits (Schuller [@b41]). The muscle nicotinic receptors are comprised of two *α*1 subunits in combination with *β*1, *γ*, and *ε* in adult skeletal muscle (Kalamida et al. [@b25]).

However, the expression of nicotinic receptors is not restricted to excitable tissues such as nerves or skeletal muscle, they were also found in epithelia of, for example, placenta (Lips et al. [@b33]), trachea (Kummer et al. [@b32]), urinary bladder (Haberberger et al. [@b18]; Beckel [@b5]), and skin (for review see Wessler and Kirkpatrick [@b50]). There is evidence that epithelial nicotinic receptors are involved in tumorgenesis in the respiratory and the gastrointestinal tract (Schuller [@b41]; Improgo et al. [@b24]). Although there are hints for the expression of nicotinic receptors in colonic epithelium, there is no study about the distribution of nicotinic receptor subunits in native colonic epithelial cells. Furthermore, it remains unclear whether nicotinic receptors are involved in the regulation of colonic ion transport, one of the fundamental functions of this tissue. Therefore, in this study, we investigated the expression of nicotinic receptor subunits in isolated colonic crypts and the effect on ion secretion of presumed nicotinic agonists across rat distal colon.

Materials and Methods
=====================

Animals
-------

Female and male Wistar rats with a body mass of 160--240 g were used. The animals were bred and housed at the Institute of Veterinary Physiology and Biochemistry of the Justus-Liebig-University at an ambient temperature of 22.5°C and air humidity of 50--55% on a 12:12 h light-dark cycle with free access to water and food until the time of the experiment. Animals were stunned by a blow on the head and killed by exsanguination (approved by Regierungspräsidium Giessen, Germany).

Solutions
---------

If not indicated differently (e.g., in ion substitution experiments), all Ussing chamber experiments were carried out in a bathing solution containing (in mmol/L): 107 NaCl, 4.5 KCl, 25 NaHCO~3~, 1.8 Na~2~HPO~4~, 0.2 NaH~2~PO~4~, 1.25 CaCl~2~, 1 MgSO~4~, and 12.2 glucose. The solution was gassed with 5% (v/v) CO~2~ and 95% (v/v) O~2~ at 37°C and had a pH of 7.4 (adjusted by NaHCO~3~/HCl). For the Cl^−^-free buffer, NaCl and KCl were equimolarly substituted by Na gluconate (NaGluc) and K gluconate (KGluc), respectively. To obtain a Ca^2+^-free buffer, CaCl~2~ was omitted from the buffer without additional administration of a Ca^2+^-chelating agent.

For crypt isolation, a Ca^2+^- and Mg^2+^-free Hanks balanced salt solution containing 10 mmol/L ethylenediaminotetraacetic acid (EDTA) was used. The pH was adjusted to 7.4 by tris(hydroxymethyl)-aminomethane. The isolated crypts were stored in a high potassium Tyrode solution consisting of (in mmol/L): 100 K gluconate, 30 KCl, 20 NaCl, 1.25 CaCl~2~, 1 MgCl~2~, 10 HEPES, 12.2 glucose, 5 Na pyruvate, and 1 g/L bovine serum albumin; pH was 7.4 (adjusted by KOH). Tissue was fixed in 100 mmol/L phosphate buffer (pH 7.4) containing 40 g/L paraformaldehyde. For the histochemical staining of acetylcholinesterase activity, a citrate buffer (100 mmol/L, pH 5.0) was used containing (in mmol/L) 2.5 CuSO~4~, 5 K~3~\[Fe(CN)~6~\], and 1 acetylthiocholine chloride. For the rehydration of the colon sections, a 100 mmol/L sodiumhydrogen maleate buffer (pH 6.0) was used.

Tissue preparation
------------------

The distal colon was quickly removed and placed in ice-cold Ussing chamber bathing solution. The colon was mounted on a thin plastic rod. A circular incision was made near the distal end with a blunt scalpel. The serosa and muscularis propria were stripped off to obtain a mucosa--submucosa preparation. This preparation was either directly used for Ussing chamber experiments or for the preparation of the mucosa. For the latter, the mucosa--submucosa was opened along the mesenteric border and placed onto a glass plate. The proximal end of the tissue was clamped with a clip. The distal end of the colon was fixed with another slide. With a sharp glass slide the mucosa was carefully separated from the submucosal layer in order to obtain a mucosa preparation.

Ussing chamber experiments
--------------------------

Either mucosa preparations (for the experiments with nicotine) or mucosa--submucosa preparations (for the experiments with choline) were fixed in a modified Ussing chamber, bathed with a volume of 3.5 mL on each side of the mucosa. The tissue was incubated at 37°C and short-circuited by a computer-controlled voltage-clamp device (Ingenieur Büro für Mess- und Datentechnik Mussler, Aachen, Germany) with correction for solution resistance. Tissue conductance (G~t~) was measured every minute by the voltage deviation induced by a current pulse (±50 *μ*A, duration 200 msec) under open-circuit conditions. Short-circuit current (*I*~sc~) was continuously recorded. *I*~sc~ is expressed as *μ*Eq/h per cm^2^, that is, the flux of a monovalent ion per time and area, with 1 *μ*Eq/h per cm^2^ = 26.9 *μ*A/cm^2^. All drugs were administered to the serosal side of the tissue. The maximal increase in *I*~sc~ evoked by an agonist is given as difference to the baseline just prior administration of the drug.

Isolation of RNA from intact colonic crypts
-------------------------------------------

The colon was rinsed with Hank's balanced salt solution. The mucosa--submucosa preparation was fixed on a plastic holder with tissue adhesive and transferred for 6 min to Hank's-EDTA solution. The tissue was vibrated for 30 sec in order to release crypts. This results in a pure preparation of viable crypts which have been intensively used for electrophysiological or imaging experiments (Schultheiss et al. [@b42]).

Crypts were collected in a high potassium Tyrode and centrifuged 3 min at 1000 g. Total RNA was isolated from the pellet using the NucleoSpin® RNA kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's protocol. Contaminating DNA was digested by rDNase (provided with the latter kit).

Reverse transcriptase polymerase chain reaction experiments
-----------------------------------------------------------

RNA was reverse transcribed with Tetro cDNA synthesis kit (Bioline, Luckenwalde, Germany) or with Superscript II cDNA synthesis kit (Life Technologies, Darmstadt, Germany). For subsequent reverse transcription polymerase chain reaction (RT-PCR) with the primer pairs (Eurofins Genomics, Ebersberg, Germany) listed in Table[1](#tbl1){ref-type="table"}, MangoMix™ mastermix (Bioline, Luckenwalde, Germany) was used with 2.5 mmol/L MgCl~2~. Due to higher sensitivity, a touchdown PCR was performed. For *α*1, *α*2, *α*3, *α*4, *α*5, *α*6, *α*9, *α*10, *β*2, and *β*3 cycling conditions were: after an initial denaturation for 10 min at 95°C, 10 cycles were run with of 95°C for 45 sec, annealing for 45 sec with an initial temperature of 67°C (decreasing by 1°C per cycle), and 72°C for 45 sec. This was followed by 30 cycles of 95°C for 45 sec, 57°C for 45 sec, 72°C for 45 min, with a final extension at 72°C for 7 min. For *α*7, *β*1, *β*4 cycling conditions were: after an initial denaturation for 10 min at 95°C, 10 cycles were run with of 95°C for 45 sec, annealing for 45 sec with an initial temperature of 71°C (decreasing by 1°C per cycle), and 72°C for 45 sec. This was followed by 30 cycles of 95°C for 45 sec, 61°C for 45 sec, 72°C for 45 min, with a final extension at 72°C for 7 min. For M~1~ and M~3~ receptors cycling conditions were as follows: after an initial denaturation for 3 min at 95°C, 10 cycles were run with of 95°C for 45 sec, annealing for 45 sec with an initial temperature of 65°C (decreasing by 1°C per cycle), and 72°C for 60 sec. This was followed by 30 cycles of 95°C for 45 sec, 55°C for 45 sec, 72°C for 60 sec, with a final extension at 72°C for 10 min. For an internal control of the PCR reaction, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used. PCR products were visualized after electrophoresis in a 2.5% (w/v) agarose gel (Peqlab, Erlangen, Germany) with GelRed™ (Biotium, Hayward, CA) or Roti®-GelStain (Roth, Karlsruhe, Germany).

###### 

Primers used for RT-PCR

             Sequence                   Product length   Accession no.   Reference
  ---------- -------------------------- ---------------- --------------- --------------------------
  *α*1                                                                   
   Forward   AACTTCATGGAGAGCGGAGA       285              NM_024485       Schirmer et al. ([@b40])
   Reverse   CAGCTCCACAATGACGAGAA                                        
  *α*2                                                                   
   Forward   CTTCGGTGAAGGAAGACTGG       154              L 10077         Lips et al. ([@b33])
   Reverse   GGAGCCAACATGAAGGACAT                                        
  *α*3                                                                   
   Forward   GCCAACCTCACAAGAAGCTC       208              NM_052805       Schirmer et al. ([@b40])
   Reverse   CCAGGATGAAAACCCAGAGA                                        
  *α*4                                                                   
   Forward   GACTTTGCAGTCACCCACCT       197              M 15682         Lips et al. ([@b33])
   Reverse   CGGCTATGCATGCTCACTAA                                        
  *α*5                                                                   
   Forward   ACCCTACCAATTTGCAACCA       146              J 05231         Lips et al. ([@b33])
   Reverse   GACCCAAAGACCCATTCTGA                                        
  *α*6                                                                   
   Forward   TGGTGTTAAGGACCCCAAAA       142              L 08227         Lips et al. ([@b33])
   Reverse   GCTGCTGGCTTAACCTCTTG                                        
  *α*7                                                                   
   Forward   GGAGGCTGTACAAGGAGCTG       446              L 31619         Lips et al. ([@b33])
   Reverse   ACCCTCCATAGGACCAGGAC                                        
  *α*10                                                                  
   Forward   TCTGACCTCACAACCCACAA       168              AF 196344       Lips et al. ([@b33])
   Reverse   TCCTGTCTCAGCCTCCATGT                                        
  *β*1                                                                   
   Forward   TCCTAAGCGTGGTGGTCCTC       151              NM_012528       Mikulski et al. ([@b36])
   Reverse   TGTGGTTCGGGTAGTTGGTC                                        
  *β*2                                                                   
   Forward   AGCCTTCTTTGGCTGTGCTC       116              NM_019297       Mikulski et al. ([@b36])
   Reverse   GAGCCGTTAGTAGCTGGACGA                                       
  *β*3                                                                   
   Forward   CACTCTGCGCTTGAAAGGAA       196              NM_133597       Mikulski et al. ([@b36])
   Reverse   GCGGACCCATTTCTGGTAAC                                        
  *β*4                                                                   
   Forward   ATGAAGCGTCCCGGTCTTGAAGTC   300              NM_052806       Liu et al. ([@b34])
   Reverse   GGTCATCGCTCTCCAGATGCTGGG                                    
  M~1~                                                                   
   Forward   GCACAGGCACCCACCAAGCAG      373              M16406          Wei et al. ([@b49])
   Reverse   AGAGCAGCAGCAGGCGGAACG                                       
  M~3~                                                                   
   Forward   GTCTGGCTTGGGTCATCTCCT      434              M16409          Wei et al. ([@b49])
   Reverse   GCTGCTGCTGTGGTCTTGGTC                                       

Sequence, expected product length of the amplificate, and gene accession code (<http://www.ncbi.nlm.nih.gov>) of the primers used. RT-PCR, reverse transcription polymerase chain reaction.

Enzyme-histochemical detection of acetylcholinesterase activity
---------------------------------------------------------------

In order to locate acetylcholinesterase activity in rat colonic epithelium, we used the method of Karnovky and Roots ([@b26]) with slight modifications (Tsuji and Larabi [@b48]). This method employs acetylthiocholine as a substrate for acetylcholinesterase. The cleavage product of the esterase activity, thiocholine, reduces ferricyanide to ferrocyanide and this in turn is precipitated by Cu^2+^ as copper ferrocyanide.

Distal colon was fixed with 40 g/L paraformaldehyde in phosphate buffer at 4°C overnight. After washing three times in phosphate buffer, the tissue was embedded in gelatin and cryofixed with N~2~-cooled isopentane. Sections (about 6 *μ*m thick) were mounted on glass slides coated with gelatin containing chromium(III) potassium sulfate (0.5 g/L). After rehydration in maleate buffer, the sections were incubated with the incubation medium overnight at 4°C. The sections were rinsed in maleate buffer again (four times for 2 min) and subsequently coverslipped. As negative control, other sections were incubated in a medium without acetylthiocholine chloride.

Drugs
-----

Bumetanide and forskolin were dissolved in ethanol (final maximal volume concentration of ethanol 2.5 mL/L). Calmidazolium, darifenacin, J104129 (Tocris, Bristol, UK), and trifluoperazine were dissolved in dimethylsulfoxide (DMSO; final maximal DMSO volume concentration 2.5 mL/L). Tetrodotoxin was dissolved in 2 × 10^2^ mol/L citrate buffer. Acetylcholine chloride, acetylthiocholine chloride, atropine, *α*-bungarotoxin (Tocris), carbachol, choline, dihydro-*β*-erythroidine (Tocris), DMPP, hexamethonium, nicotine hydrogen tartrate, pirenzepine, strychnine, and telenzepine were dissolved in distilled water. If not indicated differently, drugs were purchased from Sigma, Taufkirchen, Germany.

Statistics
----------

Results are given as mean ± standard error of the mean (SEM) with the number (*n*) of investigated tissues. For the comparison of two groups either Student's *t*-test or Mann--Whitney-*U*-test was applied. An *F*-test decided which test method had to be used. Both paired and unpaired two-tailed Student's *t*-tests were applied as appropriate. *P* \< 0.05 was considered to be statistically significant.

Results
=======

RT-PCR detection of nicotinic receptor subunits in rat colonic epithelium
-------------------------------------------------------------------------

To determine which of the nicotinic receptor subunits are expressed by rat colonic epithelium, RT-PCR was performed using mRNA from isolated crypts, that is, epithelial cells devoid of neuronal contamination, as starting material. Skeletal muscle was used as positive control for *α*1- and *β*1-subunit, for all the other subunits spinal cord served as positive control. The following subunits were consistently (in each of *n* ≥ 3 independent assays for each mRNA) detected in colonic epithelial cells: *α*2, *α*4, *α*5, *α*6, *α*7, *α*10, and *β*4. The mRNA for *β*2 was only inconsistently detected in two of five experiments (Fig.[1](#fig01){ref-type="fig"}). Not detectable in colonic epithelium, but in control tissues were the *α*1-, *α*3-, *β*1-, and *β*3-subunits. The *α*9 subunit was neither detectable in the positive control nor in the colonic epithelium, although different primers from the literature (Glowatzki et al. [@b16]; Hecker et al. [@b22]; Mikulski et al. [@b36]; Schirmer et al. [@b40]) were tested (see Discussion for possible reasons). Water controls without template did not show any amplificates (Fig.[1](#fig01){ref-type="fig"}).

![RT-PCR detection of mRNA expression of nicotinic acetylcholine receptor subunits in isolated rat colonic crypts. The agarose gel shows bands of cDNA fragments amplified using primers for *α*2 (154 bp), *α*4 (197 bp), *α*5 (146 bp), *α*6 (142 bp), *α*7 (446 bp), *α*10 (168 bp), *β*2 (116 bp), and *β*4 (300 bp). cDNA from spinal cord was used as positive, water instead of cDNA as negative control. The efficiency of RNA isolation and cDNA synthesis was verified by GAPDH-specific primers (303 bp). Each RT-PCR reaction was performed in at least three independent experiments. The mRNA for *β*2 was only inconsistently detected in two of five experiments, whereas the signals for the other nicotinic receptor subunits depicted here were found consistently. Cry, colonic crypts; SC, spinal cord; RT-PCR, reverse transcription polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.](prp20003-e00139-f1){#fig01}

Functional evidence for nicotinic receptors in rat colonic epithelium
---------------------------------------------------------------------

Ussing chamber experiments were performed with DMPP (10^−4^ mol/L), a nicotinic receptor agonist (Tapper and Lewand [@b47]), in order to investigate if there is functional evidence for the expression of nicotinic receptors in colonic epithelium. The experiments were carried out on mucosa preparations of rat distal colon (i.e., in the absence of the myenteric and the submucosal plexus) and in the continuous presence of the neurotoxin tetrodotoxin (10^−6^ mol/L) in order to prevent effects of DMPP (or nicotine) on enteric neurons of the mucosal plexus, which is still present in these preparations (Bridges et al. [@b6]). DMPP induced a transient, tetrodotoxin-resistant increase in *I*~sc~ of 2.87 ± 1.00 *μ*Eq/h per cm^2^ (*n* = 6; Fig.[2A](#fig02){ref-type="fig"}), which was suppressed, when the tissue was pretreated with the nicotinic receptor antagonist hexamethonium (10^−5^ mol/L, Fig.[2B](#fig02){ref-type="fig"}).

![Stimulation of epithelial nicotinic receptors evokes an increase in *I*~sc~. Dimethylphenylpiperazinium (DMPP, 10^−4^ mol/L) induces an increase in *I*~sc~ in the presence of tetrodotoxin (TTX; 10^−6^ mol/L) across mucosa preparations from rat distal colon (A), which was suppressed by preincubation with hexamethonium (10^−5^ mol/L; B). Values are given as means (black symbols) ± SEM (gray area), *n* = 6. Line interruptions are caused by omission of time intervals in order to synchronize the tracings of individual records to the administration of drugs.](prp20003-e00139-f2){#fig02}

The effect of DMPP was mimicked by nicotine (Fig.[3](#fig03){ref-type="fig"}). Nicotine evoked a concentration-dependent increase in *I*~sc~. For lower agonist concentrations (\<10^−4^ mol/L), the serosal compartment was washed three times with the fivefold chamber volume before the next concentration was administered. Due to an apparent desensitization of the *I*~sc~ response evoked by nicotine at higher concentrations, nicotine in concentrations ≥10^−4^ mol/L was administered only once to the same tissue. A maximal response was evoked at a concentration of 3 × 10^−4^ mol/L, which declined when the concentration was elevated to 10^−3^ mol/L probably reflecting desensitization as nicotinic receptors are well known to possess the ability to transform into the desensitized state after agonist binding without prior transition into the activated state (Giniatullin et al. [@b15]).

![Concentration-dependent increase in *I*~sc~ across mucosa preparations from rat distal colon induced by serosal administration of nicotine (in the presence of tetrodotoxin). Values are given as increase in *I*~sc~ (Δ*I*~sc~) above baseline just prior administration of the respective nicotine concentration and are means (filled circles) ± SEM (vertical lines), *n* = 6--8.](prp20003-e00139-f3){#fig03}

Sensitivity of nicotinic receptor subunit-specific inhibitors on the nicotine-induced *I*~sc~
---------------------------------------------------------------------------------------------

In order to further characterize the presumed epithelial nicotinic receptor subunits functionally, the interference of presumed subunit specific inhibitors with the secretory response induced by nicotinic receptor stimulation was tested. Inhibitors used were as follows: *α*-bungarotoxin, an inhibitor of *α*7, *α*8, and *α*9\*-subunits, strychnine, which inhibits *α*7, *α*8, *α*9*α*10-subunits, dihydro-*β*-erythroidine, an inhibitor of, for example, *α*4*β*2 and *α*3*β*2 nicotinic receptors (for references to the inhibitors used, see Chavez-Noriega et al. [@b9]; Wonnacott and Barik [@b52]), and atropine, which (in concentrations higher than those needed for muscarinic receptor blockade) has been reported to inhibit, for example, *α*3*β*2, *α*3*β*4, *α*4*β*2, or *α*4*β*4 nicotinic receptors (Parker et al. [@b39]). The preincubation for 20 min with strychnine (10^−5^ mol/L) and atropine (2.5 × 10^−5^ mol/L) significantly inhibited the increase in *I*~sc~ induced by nicotine (10^−4^ mol/L). In contrast, *α*-bungarotoxin (10^−6^ mol/L) or dihydro-*β*-erythroidine (10^−5^ mol/L) were ineffective (Fig.[4](#fig04){ref-type="fig"}). Even when the tissue was pretreated for 60 min with *α*-bungarotoxin (10^−6^ mol/L) to allow a better diffusion of this macromolecule to its presumed action sites, the nicotine-evoked increase in *I*~sc~ was unaffected, as it amounted to 6.53 ± 1.39 *μ*Eq/h per cm^2^ (*n* = 6) in the absence and 7.27 ± 1.36 *μ*Eq/h per cm^2^ (*n* = 6) in the presence of this neurotoxin.

![Effects of inhibitors of nicotinic acetylcholine receptor subunits on nicotine-evoked secretion. The *I*~sc~ induced by nicotine (10^−4^ mol/L, applied in the presence of tetrodotoxin) across colonic mucosa preparations was tested either under control conditions (open bars) or in the presence of different inhibitors of nicotinic acetylcholine receptor subunits (solid bars). Inhibitors: dihydro-*β*-erythroidine (Dh*β*E; 10^−5^ mol/L), *α*-bungarotoxin (10^−6^ mol/L), strychnine (10^−5^ mol/L), or (a high concentration of) atropine (2.5 × 10^−5^ mol/L). Values are given as increase in *I*~sc~ (Δ*I*~sc~) above baseline just prior administration of nicotine and are means ± SEM; *n* = 5--6. \**P* \< 0.05 vs. response evoked by nicotine in the respective control series.](prp20003-e00139-f4){#fig04}

Characterization of nicotinic receptor-induced anion secretion
--------------------------------------------------------------

In order to find out if the nicotine-induced *I*~sc~ is due to Cl^−^ secretion, anion substitution experiments were performed. In the presence of Cl^−^, nicotine (10^−4^ mol/L) evoked an increase in *I*~sc~ of 5.58 ± 0.97 *μ*Eq/h per cm^2^ (*n* = 8, Fig.[5](#fig05){ref-type="fig"}). However, after substitution of Cl^−^ on both sides of the tissue with the impermeable anion gluconate, the increase in *I*~sc~ was significantly reduced and only amounted to 0.86 ± 0.33 *μ*Eq/h per cm^2^ (*P* \< 0.05 vs. control, *n* = 8).

![Nicotine induces a Ca^2+^-dependent Cl^−^ secretion. The *I*~sc~ induced by nicotine (10^−4^ mol/L, applied in the presence of tetrodotoxin) across mucosa preparations from rat distal colon was either tested under control conditions (open bars) or after ion substitution or in the presence of different inhibitors of the Ca^2+^ signaling pathway, respectively (solid bars). For the Cl^−^-free solution, Cl^−^ was removed from the serosal and the mucosal compartment, for the Ca^2+^-free solution, Ca^2+^ was removed from the serosal compartment. Inhibitors: trifluoperazine (5 × 10^−5^ mol/L) and calmidazolium (5 × 10^−7^ mol/L). Values are given as increase in *I*~sc~ (Δ*I*~sc~) above baseline just prior administration of nicotine and are means ± SEM; *n* = 6--10. \**P* \< 0.05 vs. response evoked by nicotine in the respective control series.](prp20003-e00139-f5){#fig05}

Classically, nicotinic receptors function as ionotropic receptors mediating an influx of cations such as Na^+^ or Ca^2+^. As an increase in the cytosolic Ca^2+^ concentration is well known to induce epithelial Cl^−^ secretion (e.g., Diener and Schultheiss [@b11]), we tested the dependence of the epithelial nicotine response on the presence of serosal Ca^2+^. In the nominal absence of serosal Ca^2+^, the tetrodotoxin-resistant *I*~sc~ evoked by nicotine (10^−4^ mol/L) was reduced by more than 80% compared to the control group, where nicotine was administered in the presence of Ca^2+^ (*n* = 8, *P* \< 0.05 vs. response in the presence of Ca^2+^, Fig.[5](#fig05){ref-type="fig"}). One of the central enzymes involved in Ca^2+^-signaling cascades is calmodulin. In order to test the involvement of this protein in the nicotine response, two chemically different calmodulin inhibitors were used, that is, trifluoperazine (e.g., Kleene [@b30]) and calmidazolium (Worell and Frizzell [@b53]). Both inhibitors significantly reduced the nicotine-evoked increase in *I*~sc~ by more than 80% (*P* \< 0.05 for both drugs, Fig.[5](#fig05){ref-type="fig"}).

Choline induces an increase in *I*~sc~ in a concentration-dependent manner
--------------------------------------------------------------------------

Acetylcholinesterase has been detected in mucosal scrapings of the large intestine of different mammals (Sine et al. [@b44]), and the end product of the esterase reaction, choline, is known to exert affinity for different nicotinic receptors (Alkondon et al. [@b2]; Alkondon and Albuquerque [@b1]). In order to test the ability of the colonic epithelium to cleave acetylcholine and thus produce choline, which might potentially act at nicotinic receptors within the tissue, an enzyme-histochemical staining for acetylcholinesterase was performed. As can be seen in Figure[6](#fig06){ref-type="fig"}, the colonic epithelium expresses an acetylcholinesterase activity. The reaction product was observed all over the crypt axis, especially in the middle part of the crypts.

![Histochemical detection of acetylcholinesterase activity in rat colonic epithelium. (A) Lower part: muscularis propria; upper part: surface area of the colonic epithelium. For the negative control (B), acetylthiocholine in the incubation medium was omitted. Typical results from three independent experiments; scale bars: 50 *μ*m.](prp20003-e00139-f6){#fig06}

Thus we asked the question whether choline might stimulate nicotinic receptors in the colonic wall. As not only the epithelium (Fig.[6](#fig06){ref-type="fig"}) but also enteric nerves (Mestres et al. [@b35]) express high acetylcholinesterase activity, choline might be produced in close vicinity of enteric neurons, too. Therefore, for the Ussing chamber experiments with choline, a mucosa--submucosa preparation was used with an intact submucosal plexus in order not to overlook possible effects of choline at neuronal nicotinic receptors. Choline (10^−3^ mol/L to 10^−2^ mol/L) evoked a concentration-dependent increase in *I*~sc~ (Fig.[7](#fig07){ref-type="fig"}). Because a strong desensitization was observed after repeated administration of the agonist to the same tissue (data not shown), choline was administered only once to the same tissue. Desensitization might also explain why the *I*~sc~ response declined at the highest concentration tested in the concentration--response curve experiments (Fig.[7](#fig07){ref-type="fig"}).

![Concentration-dependent increase in *I*~sc~ across mucosa--submucosa preparations from rat distal colon induced by serosal administration of choline (filled circles, black solid line), Because of a desensitization, each tissue was treated with only one concentration of choline. Values are given as increase in *I*~sc~ (Δ*I*~sc~) above baseline just prior administration of the respective agonist concentration and are means (symbols) ± SEM (vertical lines), *n* = 6.](prp20003-e00139-f7){#fig07}

Sensitivity of the choline response to tetrodotoxin and cholinergic antagonists
-------------------------------------------------------------------------------

In order to investigate a possible contribution of secretomotor enteric neurons to the increase in *I*~sc~ induced by choline, the tissue was pre-incubated with tetrodotoxin (10^−6^ mol/L). However, in the presence of this neurotoxin, choline (7.5 × 10^−3^ mol/L) induced an increase of 0.36 ± 0.06 *μ*Eq/h per cm^2^ (*n* = 6), which was not different from the increase in *I*~sc~ evoked under control conditions, which amounted to 0.38 ± 0.10 *μ*Eq/h per cm^2^ (*n* = 6). Consequently, choline does not act via stimulation of neuronal cholinergic receptors.

The inhibition of nicotinic receptors with hexamethonium (10^−4^ mol/L) did not affect the choline-induced *I*~sc~ (Fig.[8](#fig08){ref-type="fig"}). However, atropine, used in a low concentration (10^−6^ mol/L) that can be expected to selectively inhibit muscarinic (and not nicotinic) receptors, reduced the choline response significantly (*P* \< 0.05 vs. control response in the absence of any inhibitor; *n* = 6; Fig.[8](#fig08){ref-type="fig"}).

![Effects of acetylcholine receptor antagonists on *I*~sc~ induced by choline across colonic mucosa--submucosa preparations. The response to choline (7.5 × 10^−3^ mol/L except the initial series with hexamethonium, where a concentration of 5 × 10^−3^ mol/L was used) was either tested under control conditions (open bars) or in the presence of different inhibitors of acetylcholine receptors (solid bars). Inhibitors: hexamethonium (10^−4^ mol/L), atropine (10^−6^ mol/L), telenzepine (10^−7^ mol/L), pirenezepine (10^−6^ mol/L), darifenacine (10^−6^ mol/L), and J104129 (5 × 10^−6^ mol/L). Values are given as increase in *I*~sc~ (Δ*I*~sc~) above baseline just prior administration of choline and are means ± SEM; *n* = 6--8. \**P* \< 0.05 vs. response evoked by choline in the respective control series.](prp20003-e00139-f8){#fig08}

In murine colonic epithelium, the two isoforms M~1~ and M~3~ of the muscarinic receptors have been described (Haberberger et al. [@b19]). In order to find out, whether M~1~ receptors were involved, the effect of choline was tested in the absence or presence of pirenzepine or telenzepine, two M~1~ muscarinic receptor antagonists (Hammer and Giachetti [@b20]; Galvan et al. [@b14]). Telenzepine (10^−7^ mol/L) tended to reduce the choline-induced *I*~sc~ as did pirenzepine (10^−6^ mol/L, Fig.[8](#fig08){ref-type="fig"}). However, these effects did not reach statistical significance. A significant inhibition, however, was observed, when the tissue was pretreated with darifenacin or J104129 (Fig.[8](#fig08){ref-type="fig"}), which inhibit M~3~ muscarinic receptors (Mitsuya et al. [@b37]; Zinner [@b55]). It can therefore be concluded that the choline-induced secretion is due to an activation of muscarinic receptors, particularly of the M~3~ subtype. Expression of both M~1~ and M~3~ muscarinic receptors in isolated rat colonic crypts was confirmed by RT-PCR experiments (Fig.[9](#fig09){ref-type="fig"}).

![RT-PCR detection of mRNA expression of muscarinic M~1~ and M~3~ acetylcholine receptor subunits in isolated rat colonic crypts. The agarose gel shows bands of cDNA fragments amplified using specific primers for M~1~ (373 bp) and M~3~ receptors (434 bp). cDNA from spinal cord was used as positive control. The efficiency of RNA isolation and cDNA synthesis was verified by using GAPDH-specific primers (303 bp). Representative results from three independent experiments. Cry, colonic crypts; SC, spinal cord; RT-PCR, reverse transcription polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.](prp20003-e00139-f9){#fig09}

In rat brain, the low-affinity stimulation of *α*7 nicotinic receptors by choline is thought to play mainly a modulatory role, as low concentrations of choline lead to a desensitization of the corresponding receptors (Alkondon et al. [@b2]). In order to investigate, whether a similar desensitization of cholinergic receptors might occur at colonic epithelium, tissues were desensitized to choline by three consecutive administrations of this agonist (10^−3^ mol/L). Indeed, the *I*~sc~ evoked by a subsequent administration of acetylcholine (10^−3^ mol/L) was significantly attenuated compared to an untreated control (Fig.[10](#fig10){ref-type="fig"}). A pretreatment with choline reduced not only the amplitude of the *I*~sc~ response, but also shortened the duration of the response (quantified as increase in *I*~sc~ above baseline 10 min after administration of acetylcholine) significantly (*P* \< 0.05). The desensitization of the acetylcholine response by choline was concentration-dependent (Table[2](#tbl2){ref-type="table"}).

###### 

Choline desensitizes the tissue against acetylcholine

  Conditions                 Acetylcholine-induced increase in *I*~sc~      *n*                                            
  -------------------------- ---------------------------------------------- ---------------------------------------------- ---
  No choline                 10.96 ± 0.97                                   3.13 ± 0.81                                    6
  10^−3^ mol/L choline       6.68 ± 1.56[\*](#tf2-2){ref-type="table-fn"}   0.58 ± 0.42[\*](#tf2-2){ref-type="table-fn"}   6
  No choline                 9.88 ± 1.68                                    2.40 ± 0.97                                    6
  5 × 10^−4^ mol/L choline   7.50 ± 1.39                                    2.34 ± 1.31                                    7
  No choline                 8.88 ± 1.73                                    1.47 ± 0.92                                    6
  10^−4^ mol/L choline       10.34 ± 1.42                                   2.52 ± 0.80                                    6

Increase in *I*~sc~ evoked by acetylcholine (10^−3^ mol/L) across mucosa--submucosa preparations from rat distal colon under control conditions ("no choline") or after pretreatment with three different concentrations of choline (administered three times in intervals of 15 min). Both the maximal increase in *I*~sc~ (peak) as well as the long-lasting rise in *I*~sc~ (measured 10 min after administration of acetylcholine) are given. Values are given as increase in *I*~sc~ above baseline just prior to administration of acetylcholine (Δ*I*~sc~) and are means ± SEM.

*P* \< 0.05 vs. response evoked by acetylcholine in the respective control series.

![Choline desensitizes the tissue against acetylcholine. Acetylcholine (10^−3^ mol/L) induces a long-lasting increase in *I*~sc~ across mucosa--submucosa preparations under control conditions (A), which is desensitized by three prior administrations of choline (10^−3^ mol/L; B). Values are given as means (symbols) ± SEM (lines), *n* = 6--7. Line interruptions are caused by omission of time intervals in order to synchronize the tracings of individual records to the administration of drugs. For statistics, see Table[2](#tbl2){ref-type="table"}.](prp20003-e00139-f10){#fig10}

Ionic nature of the *I*~sc~ response to choline
-----------------------------------------------

Replacing Cl^−^ in the buffer solution by the impermeant anion gluconate reduced the *I*~sc~ evoked by choline (7.5 × 10^−3^ mol/L) by 75% (*n* = 7--8, *P* \< 0.05, Table[3](#tbl3){ref-type="table"}). A similar inhibition was observed in the presence of bumetanide (10^−4^ mol/L), an inhibitor of the Na^+^-K^+^-2Cl^−^ cotransporter responsible for the basolateral uptake of Cl^−^ during Cl^−^ secretion (*n* = 7--8, *P* \< 0.05, Table[3](#tbl3){ref-type="table"}). Thus the choline-induced *I*~sc~ is mediated by Cl^−^ secretion.

###### 

Choline-induced *I*~sc~ is carried by Cl^−^ secretion

  Conditions           Choline-induced increase in *I*~sc~ (Δ*I*~sc~; *μ*Eq/h per cm^2^)   *n*
  -------------------- ------------------------------------------------------------------- -----
  With chloride        1.25 ± 0.30                                                         7
  Without chloride     0.30 ± 0.19[\*](#tf3-2){ref-type="table-fn"}                        8
  Without bumetanide   0.64 ± 0.18                                                         7
  With bumetanide      0.15 ± 0.03[\*](#tf3-2){ref-type="table-fn"}                        8

Chloride dependency of the *I*~sc~ response evoked by choline (7.5 × 10^−3^ mol/L) across mucosa--submucosa preparations from rat distal colon. For each experimental series, the response to choline was tested in the presence of bumetanide (10^−4^ mol/L) or after chloride substitution (at the mucosal and serosal side), respectively, and compared to the response under control conditions. Values are given as increase in *I*~sc~ above baseline just prior to administration of choline (Δ*I*~sc~) and are means ± SEM.

*P* \< 0.05 vs. response evoked by choline in the respective control series.

Discussion
==========

This study shows that nicotinic receptors are expressed in colonic epithelial cells and that a stimulation of these receptors induces an anion secretion across colonic epithelium. The nicotinic agonist DMPP induces a transient increase in *I*~sc~ across mucosa preparations, that is, preparations devoid of the submucosal and the myenteric plexus. In order to prevent effects of DMPP on enteric neurons of the mucosal plexus, the experiments were carried out in the continuous presence of the neurotoxin tetrodotoxin, suppressing the propagation of action potentials. The response to DMPP was inhibited by a preincubation with hexamethonium (Fig.[2](#fig02){ref-type="fig"}) supporting the assumption that there are functional nicotinic receptors on the colonic epithelium. Also another agonist at nicotinic receptors, nicotine itself, induced a concentration-dependent increase in *I*~sc~ (Fig.[3](#fig03){ref-type="fig"}), which was carried by a Ca^2+^-dependent Cl^−^ secretion (Fig.[5](#fig05){ref-type="fig"}). Classically, nicotinic receptors function as ionotropic receptors mediating an influx of cations such as Na^+^ or Ca^2+^. An increase in the cytosolic Ca^2+^ concentration is well known to induce epithelial Cl^−^ secretion (e.g., Diener et al. [@b12], Diener and Schultheiss [@b11]).

The transient time course of secretion induced by nicotinic agonists is in agreement with the effect of other Ca^2+^-dependent secretagogues. This is not only observed for endogenous agonists such as acetylcholine (Fig.[10](#fig10){ref-type="fig"}), which are quickly degraded enzymatically (in this case by the acetylcholine esterase expressed by the epithelium, Fig.[6](#fig06){ref-type="fig"}), as also the response to esterase-resistant acetylcholine derivatives (like carbachol) is only transient (Strabel and Diener [@b45]). As the increase in the cytosolic Ca^2+^ concentration evoked by Ca^2+^-dependent secretagogues lasts much longer than the secretory response of the epithelium (Diener et al. [@b13]), an active downregulation of transporters involved in anion secretion is generally assumed, which might involve release of fatty acids by activation of Ca^2+^-dependent phospholipase A~2~, which then inhibits ion channels (Devor and Frizzell [@b10]), a transactivation of receptors for epithelial growth factor (Keely and Barrett [@b27]), or internalization of the Na^+^-K^+^-Cl^−^ cotransporter (NKCC1) thus reducing basolateral Cl^−^ uptake (Calvo Del Castillo et al. [@b8]).

The RT-PCR experiments showed the consistent expression of various nicotinic receptor subunits, namely *α*2, *α*4, *α*5, *α*6, *α*7, *α*10, and *β*4, whereas the *β*2 subunit transcripts were found only in a part (40%) of the samples (Fig.[1](#fig01){ref-type="fig"}). For the *α*9 subunit, no amplification product was detected neither in the control tissue nor in the colonic epithelium. Mikulski et al. ([@b36]) also described problems with the detection of the *α*9 subunit in rat alveolar macrophages. They were able to detect the *α*9 subunit only when using the Superscript II (Life Technologies, Darmstadt, Germany) reverse transcriptase system (for discussion of possible reasons, see Mikulski et al. [@b36]). However, even with this method to prepare cDNA from isolated crypts (and other tissues such as skin, urothelium or spinal cord), we were unable to detect a transcript (data not shown), which might indicate a low stability of the corresponding mRNA. A proof of these mRNA expression patterns on the protein level was not possible due to the lack of suitable antibodies (e.g., Moser et al. [@b38]). However, in accordance with our observations at native colonic epithelium, transcripts of various nicotinic receptor subunits (i.e., *α*4, *α*5, *α*7, and *β*1) have been detected by RT-PCR in the human colonic epithelial tumor cell line HT29 and shown to be involved in cytokine release (Summers et al. [@b46]) and cell proliferation (Wong et al. [@b51]).

Theoretically, the expression of the nicotinic receptor subunits found (Fig.[1](#fig01){ref-type="fig"}) would enable the formation of several nicotinic receptor subtypes such as homopentameric *α*7 or heteromers of *α*2*β*4, *α*4*β*4, and *α*5*α*7*β*4. For investigating the functional significance of the nicotinic receptor subunits expressed, we performed experiments with selective antagonists of different nicotinic receptor subunits. The preincubation of the tissue with dihydro-*β*-erythroidine, a potent inhibitor of, for example, *α*4*β*2 and *α*3*β*2 nicotinic receptors (Chavez-Noriega et al. [@b9]; Wonnacott and Barik [@b52]), as well as a preincubation with *α*-bungarotoxin, an inhibitor of *α*7, *α*8, and *α*9\* receptors, did not affect the increase in *I*~sc~ evoked by nicotine (Fig.[4](#fig04){ref-type="fig"}). In contrast, the nicotine response was significantly inhibited after a preincubation with the *α*7, *α*8, *α*9/*α*10 receptor antagonist strychnine or atropine (Fig.[4](#fig04){ref-type="fig"}). Atropine, although being the classical antagonist of muscarinic receptors, is known since long to inhibit -- at higher concentrations -- nicotinic receptors, too (Ambache [@b3]), an effect, which can also be seen on the level of acetylcholine- or nicotine-evoked inward currents at Xenopus oocytes heterologously expressing human nicotinic receptors (Zwart and Vijverberg [@b56]). Atropine has been reported to inhibit, for example, *α*3*β*2, *α*3*β*4, *α*4*β*2, or *α*4*β*4 receptors (Parker et al. [@b39]). This might -- at first glance -- allow different combinations of functional strychnine-sensitive (e.g., *α*10\*) or atropine-sensitive (e.g., *α*4*β*4) epithelial nicotinic receptors when combining the inhibitor experiments (Fig.[4](#fig04){ref-type="fig"}) with the expression data (Fig.[1](#fig01){ref-type="fig"}). However, the observed inhibitor profile differs from classical observations obtained with nicotinic receptor subunit combinations from excitable tissues in two aspects. Usually, strychnine (blocker of *α*7, *α*8, *α*9*α*10-subunits) and *α*-bungarotoxin (blocker of *α*7, *α*8, and *α*9\*-subunits) have a similar pharmacological profile, but at rat colonic epithelium only strychnine was an effective inhibitor. Furthermore, after heterologous expression of the corresponding human subunits in Xenopus oocytes, the atropine-sensitive heteromer *α*4*β*4 is highly sensitive to dihydro-*β*-erythroidine, which also proved to be without effect at rat colonic epithelium (Fig.[4](#fig04){ref-type="fig"}). Whether species differences or variations in the subunit combinations of nicotinic receptors between excitable and nonexcitable cells are responsible for this discrepancy, finally remains open. Furthermore, strychnine might have other effects such as, for example, the inhibition of glycine receptors, where strychnine acts as a classical antagonist (e.g., Grenningloh et al. [@b17]). Nevertheless, the observation that hexamathonium abolishes the tetrodotoxin-resistant increase *I*~sc~ evoked by nicotinic agonists (Fig.[2](#fig02){ref-type="fig"}) together with the expression data on mRNA level (Fig.[1](#fig01){ref-type="fig"}) clearly shows a functional role of epithelial nicotinic receptors, although their subunit stoichiometry remains undefined.

A further unexpected result of this study was the observation that choline has the ability to act as an agonist of epithelial muscarinic receptors and thereby induces a Cl^−^ secretion across the colonic epithelium (Fig.[7](#fig07){ref-type="fig"}, Table[3](#tbl3){ref-type="table"}). Choline is a cleavage product of the hydrolysis of acetylcholine by acetylcholinesterases. Mucosal intestinal scrapings from various mammals are known to express high cholinesterase activity (Sine et al. [@b44]). This study confirmed the expression of cholinesterase in rat colonic epithelium by histochemical staining demonstrating high cholinesterase activity all over the crypt axis (Fig.[6](#fig06){ref-type="fig"}). Since the histochemical assay was performed without addition of iso-tetraisopropylpyrophosphoramide (OMPA) (due to its high toxicity), a specific inhibitor of the butyrylcholinesterase (Koelle et al. [@b31]), it is not possible to differentiate if the reaction product is due to an acetylcholinesterase or butyrylcholinesterase activity.

Choline is well known for its affinity to some nicotinic receptors. For example, choline has been described as full agonist of *α*7 nicotinic receptors in rat neurons and as partial agonist of nicotinic receptors containing *α*3*β*4\* subunits (Alkondon et al. [@b2]). In contrast, on nicotinic *α*4*β*4\* receptors choline acts as an antagonist (Alkondon and Albuquerque [@b1]). Thus, we had expected that -- if choline might be able to induce changes in electrogenic ion transport -- the response to choline would be mediated by a stimulation of the nicotinic receptors found in the functional (Figs.[4](#fig04){ref-type="fig"}) and RT-PCR (Fig.[1](#fig01){ref-type="fig"}) experiments. However, although choline induced a tetrodotoxin-resistant Cl^−^ secretion across rat colonic epithelium, this effect was unaffected by hexamethonium (Fig.[8](#fig08){ref-type="fig"}). In contrast, the choline-induced *I*~sc~ was inhibited by the nonselective muscarinic antagonist atropine (Fig.[8](#fig08){ref-type="fig"}). Because M~1~ as well as M~3~ muscarinic receptors have been described to be expressed in murine colonic epithelium (Haberberger et al. [@b19]), the effect of choline was tested in the presence of specific antagonists of M~1~ or M~3~ acetylcholine receptors. Inhibition of M~3~ muscarinic receptors with darifenacin or J104129 significantly inhibited the increase in *I*~sc~ evoked by choline (Fig.[8](#fig08){ref-type="fig"}). Thus choline induces an activation of epithelial muscarinic receptors in rat distal colon resulting in a Cl^−^ secretion. Although choline is well known for its affinity to nicotinic receptors (see above), in the literature at least in one tissue muscarinic effects of choline have been described, that is, the stimulation of muscarinic receptors on atrial myocytes from canine and guinea pig heart (Shi et al. [@b43]).

The physiological relevance for direct stimulation of muscarinic epithelial receptors by choline, the degradation product of acetylcholine, is probably low. Millimolar concentrations of choline are required to induce an increase in *I*~sc~ and even at the highest concentration used (10^−2^ mol/L) only a small secretory response was evoked by this agonist (Fig.[7](#fig07){ref-type="fig"}), suggesting that choline might act only as partial agonist. Furthermore, considering, for example, the physiological plasma concentration of choline, which amounts to about 10 *μ*mol/L in humans (Zeisel [@b54]), it is quite improbable that millimolar concentrations are reached in vivo, although the cleavage of acetylcholine by esterases might transiently result in higher local concentrations of choline. However, for the action of choline at *α*7 nicotinic receptors in rat brain, a modulatory role of low concentrations of choline has been proposed, as these concentrations lead to a desensitization of the corresponding receptors (Alkondon et al. [@b2]). A similar desensitization by choline of the acetylcholine-induced *I*~sc~ was observed in the colonic epithelium (Fig.[10](#fig10){ref-type="fig"}), suggesting that in vivo the degradation product of acetylcholine might well be able to modify cholinergic signaling to the epithelium.

Taken together the present experiments reveal a more complex cholinergic regulation of epithelial ion transport in colonic mucosa than previously thought. Acetylcholine, produced both by enteric neurons (Harrington et al. [@b21]) as well as by the colonic epithelium (Klapproth et al. [@b29]; Bader et al. [@b4]) modulates anion secretion both by epithelial muscarinic and by epithelial nicotinic receptors and also its degradation product, choline, is able to modify cholinergic transmission.
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DMPP

:   dimethylphenylpiperazinium
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:   dimethylsulfoxide

EDTA
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:   glyceraldehyde-3-phosphate dehydrogenase
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:   short-circuit current

RT-PCR

:   reverse transcription polymerase chain reaction
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